Evidence map›Paper›PMID 40721878›Full record

ArticleProstate cancer and prostatic diseases2026

5G-remote radical prostatectomy under novel robotic systems: a prospective comparative cohort study with local surgeries.

Sunyi Ye, Ding Peng, Lixian Zhu, Yi Zhu, Anbang He, Taile Jing, Xiaolin Yao, Shilong Wei, Qianqian Zhao, Jieyin Chen and 7 more

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Sunyi Ye *Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
Ding Peng *Department of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.ORCID http://orcid.org/0000-0002-2252-1304
Lixian Zhu *Department of Thyroid Surgery, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
Yi ZhuDepartment of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
Anbang HeDepartment of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
Taile JingDepartment of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
Xiaolin YaoDepartment of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
Shilong WeiOperating Room Department, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
Qianqian ZhaoOperating Room Department, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
Jieyin ChenOperating Room Department, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
Yanle YeDepartment of Urology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian Province, People's Republic of China.
Jingshuang CaiDepartment of Urology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian Province, People's Republic of China.
Jin ZhouDepartment of Urology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian Province, People's Republic of China.
Ping WangDepartment of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China.
Zhiyang HuangDepartment of Urology, Quanzhou First Hospital Affiliated to Fujian Medical University, Quanzhou, Fujian Province, People's Republic of China. hzy8902@126.com.
Shuo WangDepartment of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China. shuowang11@zju.edu.cn.
Dan XiaDepartment of Urology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang Province, People's Republic of China. xiadan@zju.edu.cn.ORCID http://orcid.org/0000-0002-5256-3900

Funding

Natural Science Foundation of Zhejiang Province (Zhejiang Provincial Natural Science Foundation) LQ23H160027Science and Technology Department of Zhejiang Province 2024C03198
6 · The paper itself

Abstract

backgroundThere is no report upon the remote surgery of radical prostatectomy and comparisons between local surgeries. This study aims to evaluate the feasibility and safety of the innovative remote tele-surgical robotic platforms in performing radical prostatectomy.

methodsThe study comprised 13 patients diagnosed with prostate cancer who underwent remote radical prostatectomy using a 5 G wireless network and the innovative remote robotic systems (Tele-RARP). Additionally, the research involved 31 patients who underwent radical prostatectomy with the local Toumai robotic system (TM-RARP) between October 2022 and April 2024, and 36 patients who underwent radical prostatectomy with the da Vinci Xi platform (Xi-RARP) during the same period under the supervision of the same surgical team. Data on demographics, perioperative factors, clinicopathologic information, and postoperative results were collected for a total of 80 patients.

resultsThe completion of 13 Tele-RARP procedures was successful without significant intraoperative or postoperative issues. No instances of intraoperative blood transfusion or surgical conversion were reported. The operation, console, and docking time for both the remote and local surgeries showed minimal differences. Neither local nor remote surgery nor da Vinci Xi surgery exhibited significant variations in terms of blood loss, intraoperative complications, or postoperative prognosis. Both TM-RARP and Tele-RARP presented very manageable task loads.

conclusionsPerforming tele-surgical robotic-assisted radical prostatectomy using the innovative Toumai and Edge robotic surgical systems via a 5 G wireless network is not only feasible but also safe. REGISTRATION NUMBER: ChiCTR2400085386, ChiCTR2300077721.

Indexed as

ProstatectomyProstatic NeoplasmsRobotic Surgical ProceduresAgedHumansMaleMiddle AgedPostoperative ComplicationsProspective Studies

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.